Cargando…

Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents

The assessment report formats of four major regulatory reference agencies, US Food and Drug Administration, European Medicines Agency, Health Canada, and Australia's Therapeutic Goods Administration were compared to a benefit-risk (BR) documentation template developed by the Centre for Innovati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leong Wai Yeen, James, Salek, Sam, Walker, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255503/ https://www.ncbi.nlm.nih.gov/pubmed/25538620 http://dx.doi.org/10.3389/fphar.2014.00269

Ejemplares similares

A practical approach to communicating benefit-risk decisions of medicines to stakeholders
por: Leong, James, et al.
Publicado: (2015)

Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication?
por: Keyter, Andrea, et al.
Publicado: (2020)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

The South African Regulatory System: Past, Present, and Future
por: Keyter, Andrea, et al.
Publicado: (2018)

The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making
por: Donelan, Ronan, et al.
Publicado: (2016)

Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Koyuncu, Oguzhan, et al.
Publicado: (2020)

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

Assessment of the effectiveness and efficiency of the West Africa medicines regulatory harmonization initiative by the member countries
por: Owusu-Asante, Mercy, et al.
Publicado: (2022)

Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Keyter, Andrea, et al.
Publicado: (2019)

Assessment of the effectiveness and efficiency of the economic community of West African States Medicines Regulatory Harmonization initiative by the pharmaceutical industry
por: Owusu-Asante, Mercy, et al.
Publicado: (2023)

A Proposed Regulatory Review Model to Support the South African Health Products Regulatory Authority to Become a More Efficient and Effective Agency
por: Keyter, Andrea, et al.
Publicado: (2020)

South African Regulatory Authority: The Impact of Reliance on the Review Process Leading to Improved Patient Access
por: Keyter, Andrea, et al.
Publicado: (2021)

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022)

Decisions by regulatory agencies: are they evidence-based?
por: Furberg, Curt D
Publicado: (2007)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
por: Keyter, Andrea, et al.
Publicado: (2019)

Medication-Related Readmissions: Documentation of the Medication Involved and Communication in the Care Continuum
por: Lee, Ze-Yun, et al.
Publicado: (2022)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore
por: Mashaki Ceyhan, Emel, et al.
Publicado: (2018)

Evaluation of the Effectiveness and Efficiency of the East African Community Joint Assessment Procedure by Member Countries: The Way Forward
por: Ngum, Nancy, et al.
Publicado: (2022)

Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement
por: Ngum, Nancy, et al.
Publicado: (2022)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
por: Rahalkar, Hasumati, et al.
Publicado: (2018)

Public availability of information from WFME-recognized accreditation agencies
por: Baniadam, Kahlo, et al.
Publicado: (2021)

Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure
por: Singh, Vijay K., et al.
Publicado: (2021)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
por: Bujar, Magdalena, et al.
Publicado: (2020)

Available documents
por: CERN Press Office. Geneva
Publicado: (1974)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Characteristics of drug safety alerts issued by the Spanish Medicines Agency
por: Montané, Eva, et al.
Publicado: (2023)

Building organizational reputation in the European regulatory state: An analysis of EU agencies' communications
por: Rimkutė, Dovilė
Publicado: (2019)

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022)

Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities
por: Sithole, Tariro, et al.
Publicado: (2021)

Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
por: Jonker, Carla J., et al.
Publicado: (2022)

Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities
por: Danks, Lorraine, et al.
Publicado: (2023)

Epidemiological studies for regulatory agencies.
por: Hunt, V R
Publicado: (1981)

Communications in the time of a pandemic: the readability of documents for public consumption
por: Ferguson, Catherine, et al.
Publicado: (2021)

The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System
por: Keyter, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fes32kj1t5lv8ghpd5qq1dkm81